- Home
- CVM vs BGLC Comparison
CVM vs BGLC Comparison
Compare CVM & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVM
- BGLC
- Stock Information
- Founded
- CVM 1983
- BGLC 2017
- Country
- CVM United States
- BGLC Malaysia
- Employees
- CVM N/A
- BGLC N/A
- Industry
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- BGLC Medical Specialities
- Sector
- CVM Health Care
- BGLC Health Care
- Exchange
- CVM Nasdaq
- BGLC Nasdaq
- Market Cap
- CVM 11.8M
- BGLC 10.7M
- IPO Year
- CVM 1987
- BGLC N/A
- Fundamental
- Price
- CVM $3.46
- BGLC $5.09
- Analyst Decision
- CVM
- BGLC
- Analyst Count
- CVM 0
- BGLC 0
- Target Price
- CVM N/A
- BGLC N/A
- AVG Volume (30 Days)
- CVM 1.6M
- BGLC 2.7M
- Earning Date
- CVM 08-14-2025
- BGLC 08-13-2025
- Dividend Yield
- CVM N/A
- BGLC N/A
- EPS Growth
- CVM N/A
- BGLC N/A
- EPS
- CVM N/A
- BGLC N/A
- Revenue
- CVM N/A
- BGLC $9,265,870.00
- Revenue This Year
- CVM N/A
- BGLC N/A
- Revenue Next Year
- CVM N/A
- BGLC N/A
- P/E Ratio
- CVM N/A
- BGLC N/A
- Revenue Growth
- CVM N/A
- BGLC N/A
- 52 Week Low
- CVM $1.98
- BGLC $2.01
- 52 Week High
- CVM $66.60
- BGLC $15.60
- Technical
- Relative Strength Index (RSI)
- CVM 57.66
- BGLC 52.61
- Support Level
- CVM $2.24
- BGLC $5.33
- Resistance Level
- CVM $2.71
- BGLC $6.39
- Average True Range (ATR)
- CVM 0.51
- BGLC 1.18
- MACD
- CVM 0.25
- BGLC 0.10
- Stochastic Oscillator
- CVM 25.61
- BGLC 19.15
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.